Drug intelligence / Profile preview

Zeng-xiao An-shen Zhi-chan 2

Development stage: Unknown
Administration: Oral

Overview

Zeng-xiao An-shen Zhi-chan 2 (ZAZ2) is a traditional Chinese medicine (TCM) that has been evaluated for its effects on patients with Parkinson's disease (PD). Clinical studies have indicated that ZAZ2 can improve activities of daily living (ADL) in parkinsonism, as well as enhance awake-sleep rhythm and improve scores on the Unified Parkinson Disease Rating Scale (UPDRS) Parts II, II+III, and IV. It also positively impacts the power-law exponent α, which correlates with physical activity levels. These findings suggest ZAZ2 could be a suitable drug for long-term use in managing PD symptoms.

Beyond the preview

Go deeper on Zeng-xiao An-shen Zhi-chan 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zeng-xiao An-shen Zhi-chan 2.

Explore the full profile